|
The following information was reported to gore:
on (b)(6) 2026, a patient underwent a total arch replacement with the elephant trunk technique to treat a thoracic aortic aneurysm.On (b)(6) 2026, the patient underwent endovascular treatment using gore® dryseal flex introducer sheath and gore tag conformable thoracic stent grafts with active control system (ctagac) devices.The devices were deployed continuously with the elephant trunk.The sheath and ctagac were difficult to advance into the elephant trunk due to the steepness of the arch.The physician attempted to hold the sheath under the elephant trunk and to advance the ctagac when a dissection formed in the descending aorta associated with the tip of the sheath.The primary entry was closed with the ctagac.The false lumen flow was resolved.However, re-entry was still observed in the ventral branch.No special treatment was performed for re-entry.The patient tolerated the procedure.
|
|
H6: a review of the manufacturing records for the device verified that the lot met all pre-release specifications.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|